08:14 AM EDT, 06/06/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Thursday that data from the investigational combination of bulevirtide 10 milligram with pegylated interferon alfa-2a, or PegIFN, was "superior" to investigational bulevirtide 10 mg monotherapy for the treatment of compensated chronic hepatitis delta virus infection.

The company is evaluating the efficacy and safety of bulevirtide as monotherapy and in combination with PegIFN in a phase 2b MYR204 open-label trial, Gilead added.

The data, published in the New England Journal of Medicine, demonstrated the combination of bulevirtide 10 mg with PegIFN retained a 46% rate of undetectable hepatitis delta virus RNA at week 48 after the end of the treatment, the biopharmaceutical firm said.

The safety profiles of bulevirtide in combination with PegIFN were "consistent" as compared to the individual components, the company said. Leukopenia, neutropenia, and thrombocytopenia were the most frequent adverse events, and the majority were mild to moderate.

Bulevirtide 10 mg is an investigational product and has not been approved anywhere, according to the company.

Price: 63.92, Change: +0.04, Percent Change: +0.06